MET and renal cell carcinoma: According to CTRP drug sensitivity analysis, high level of CBX2, BLNK, PLK4, STIL and BIRC5 were associated with increased sensitivity to inhibitors of VEGF and MET pathways, which happened to be two crucial driver pathways of renal cell carcinoma [32,33].